<DOC>
	<DOCNO>NCT01447420</DOCNO>
	<brief_summary>This multi-center , open-label study evaluate efficacy safety Pegasys ( peginterferon alfa-2a ) Copegus ( ribavirin ) relation IL28-b gene expression treatment-naïve patient chronic hepatitis C genotype 1 . Patients receive Pegasys ( 180 mcg sc weekly ) Copegus ( 1'000 1'200 mg orally daily ) 48 week . Anticipated time study treatment 48 week , follow-up 24 week .</brief_summary>
	<brief_title>A Study Sustained Virological Response Relation IL28-b Expression Treatment-Naïve Patients With Chronic Hepatitis C Genotype 1 Combination Treatment With Pegasys ( Peginterferon Alfa-2a ) Copegus ( Ribavirin )</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Adult patient , &gt; /=18 &lt; 70 year age initiation treatment Body weight 50 kg 125 kg baseline Chronic hepatitis C , genotype 1 Chronic liver disease consistent HCV infection Compensated liver disease ( ChildPugh Grade A ) Pregnant lactate woman , male partner pregnant woman Chronic hepatitis C , genotype 2 , 3 , 4 , 5 6 Previous treatment interferon ribavirin Positive hepatitis A , hepatitis B HIV infection History evidence medical condition associate liver disease chronic hepatitis C Decompensated liver disease and/or liver disease ChildPugh classification &gt; 6 Hepatocellular carcinoma History evidence esophageal bleed Hemoglobinopathy , cause possible hemolysis Hb &lt; 11 g/dL woman , &lt; 12 g/L male</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>69 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>